About the BrainTech Alliance
If it takes a village to raise a child, it takes an ecosystem to scale a DeepTech startup. The BrainTech Alliance brings together visionary investors, the best academic researchers, and ambitious entrepreneurs to help innovation go from the Lab to the World.
.png)
Our guiding principles
We believe that understanding the human brain is one of Humanity’s greatest challenges. In this pursuit, we aim to drive meaningful advancements in education, mental health, and medical science. Our mission is to translate scientific discoveries into actionable innovations that enhance the diagnosis, treatment, and management of neurological and psychiatric conditions.
We are committed to those who rely on these innovations—patients, families, caregivers, doctors, medical professionals, scientists, and educators. We owe it to our communities to develop solutions that are not only cutting-edge but also practical, accessible, and sustainable. This means ensuring that our technologies are reliable, easy to use, and scalable. It also means establishing sound business models that reinvest in the next generation of innovation, creating a continuous cycle of progress.
As investors, sponsors, and industry leaders, we recognize that sustainable success requires balancing impact with return on investment—whether monetary or societal. We believe that measurable improvements in brain health and well-being define success as much as financial returns.
We acknowledge that science is experimental and that true innovation comes with risk. We embrace these risks and the lessons they bring, fostering a culture of resilience, adaptability, and shared learning. We also recognize the fragility of human life and commit to supporting one another in times of needs. Only through mutual understanding, benevolence, and collaboration can we build a thriving, inclusive, and enduring ecosystem.
At the heart of innovation is community. It takes an ecosystem to raise a startup—and through collective effort, we will transform brain science into real-world impact.
Our Founding Members
A select club of 200 of the World's best academic Institutions, Specialized VCs, Ambitious LPs, Brain focused Startups. Together we represent over $2bn in capital under management, over 1000 scientific publications, and over 100 patents.
Aayush C. (ARIA, United Kingdom), Abirami J. (The Grae Matta Foundation, United Kingdom), Adam K. (Neuro VC, USA), Adrian H. (Team Consulting, United Kingdom), Alastair M. (Mendea Technologies, United Kingdom), Alex K. (University of Washington School of Medecine, USA), Alexis G. (French Armed forces Ministry, France), Allie W. (University of Cambridge, United Kingdom), Amandine A. (French National Centre for Scientific Research, France), Amy K. (Satori Capital, USA), Andrew A. (Dark Arts VC, USA), Anne V. (King's College London, United Kingdom), Anjum R. (EQT Foundation, United Kingdom), Anne-Laure M. (Apposite Capital, United Kingdom), Anne-Sophie S. (Newfund, France), Arielle L. (Medtronic, United Kingdom), Arkady K. (RPV, USA), Arnaud A. (Cathay Innovation, USA), Assi H. (Brainvivo, Israel), Augusta P. (Aisel Health, United Kingdom), Avery K. (Constellation, USA), Aydin B. (UCLA, USA), Benjamin T. (Biohybrid Devices, United Kingdom), Bernadine L. (QuantumCyte, USA), Bertrand D. (Robeauté, France), Blake G. (Humanity Neurotech, USA), Boris C. (Université Paris Cité, France), Brian P. (Rune Labs, USA), Bruce S. (Purdue University, USA), Caitlin N. (Psymed Ventures, Spain), Catalin M. (Netholabs, United Kingdom), Charles N. (Synergia Medical, Belgium), Chenming C. (PETcoil, USA), Chris M. (NeuraWorx, USA), Christian L. (Netholabs, USA), Christine L. (Banque Delubac, France), Christof G. (University of Cambridge, United Kingdom), Christoph D. (Mimo.fit, USA), Colin K. (NeuroSigma, USA), Dan R. (Nuri Braintech, Israel), David M. (Humanity Neurotech, USA), Darius G. (Imperial Collegue NeuroTech Society, United Kingdom), David C. (Vanderbilt University, USA), Davide D. (Migration Biotherapeutics Limited, United Kingdom), Diana R. (LifeArc Ventures, United Kingdom), Dominic J. (Index Ventures, United Kingdom), Dorian A. (Provect.ai, USA), Dorian H. (MintNeuro, United Kingdom), Edward R. (Nexus NeuroTech Ventures, USA), Elise K. (American Heart Association Venture group, USA), Emil H. (BIOS, United Kingdom), Emile R. (Samphire Neuroscience, USA), Emilie S. (Zinc, United Kingdom), Jake F. (Vanderbilt University Medical Center, USA), Emily M. (SynchNeuro, USA), Emmanuelle P. (Consulate General of France in San Francisco, USA), Erin G. (Stanford University, USA), Erki M. (Verge HealthTech Fund, Estonia), Florence S. (Siskal, France), Florian B. (Nurea, France), Florian H. (TruVenturo GmbH, Austria), François V. (Newfund, France), Gerard F. (Université Paris Cité, France), Gillian K. (ARIA, United Kingdom), Harith A. (UCL, United Kingdom), Henri D. (Newfund, USA), Holly B. (Wellcome Leap, United Kingdom), Ishan K. (USA), Irakli K. (Stanford University, USA), Jack S. (Leo Lion, United Kingdom), Jacques C. (ARIA, United Kingdom), Jake C. (The Francis Crick Institute, United Kingdom), James C. (NeuroTech Reports, USA), James M. (UCSF, USA), James T. (Artificial Intelligence Centre for Value Based Healthcare, United Kingdom), Jane O. (SONA, United Kingdom), Jared S. (Imperial College London, United Kingdom), Jean-Luc A. (Symmetry, United Kingdom), Jin L. (IMIDeology, USA), Joana C. (Robeaute, France), Joao B. (re.Mind, United Kingdom), Joe H. (Dragonfly 44 Capital, USA), John B. (Kadence Bio, United Kingdom), John P. (Nexus Neurotech, USA), John Y. (CryoTherapeutics SA, Germany), John Z. (UC Berkeley, USA), JoJo P. (The Platt Associates, USA), Jon F. (Peter, United Kingdom), Jon L. (Nexus Neurotech, USA), Jonah P. (Lexi VC, USA), Joonas J. (Soihtu DTx, Finland), Jordi P. (Nexus Neurotech, USA), Josef G. (Imperial College London, United Kingdom), Juan-Pablo M. (Action Potential VC, USA), Julie R. (Braintale, USA), Jun A. (E11 Bio, USA), Justin S. (Paradromics, USA), Kamila J. (MIT and University of Cambridge, United Kingdom), Kat S. (King's College London, United Kingdom), Kira P. (Asteria Institute, USA), Kultar G. (Flow Neuroscience, United Kingdom), Larry S. (COINS, United Kingdom), Liam C. (Cambridge NeuroWorks, United Kingdom), Lise R. (Milner Therapeutics Institute, United Kingdom), Mahnaz A. (The University of Sheffield, United Kingdom), Marjolaine B. (Imperial College London, United Kingdom), Mark R. (NeuralPulse, USA), Mark V. (Eads Bridge Holdings, USA), Matias S. (Psymed Ventures, USA), Matt A. (Paradromics, USA), Michael B. (Dragonfly 44 Capital, USA), Michael J. (Foothill Ventures, USA), Miri P. (Nuri Braintech, Israel), Myles F. (Eolas Medical, United Kingdom), Naunehal M. (London Institute for Healthcare Engineering, United Kingdom), Nicholas I. (Archimed Group, United Kingdom), Nikhil J. (Cellular Vehicles, USA), Oybek K. (Cornell Tech, USA), Parnian L. (Olfera Tx, USA), Pascal J. (Convergence Partners, United Kingdom), Patrick M. (Amaranth Foundation, USA), Patrick S. (Neubond, United Kingdom), Paul B. (The Royal London Hospital, United Kingdom), Paul H. (Raidium, France), Paul L. (BrainCapture, United Kingdom), Paul M. (PXN Group, United Kingdom), Paul S. (King's College London, United Kingdom), Pawel S. (NeuroCentury, Belgium), Pekka S. (Innovestor, Finland), Peng C. (UCSF, USA), Pierre F. (Newfund Heka, France), Pierre M. (Raidium, France), Peter B. (Romily Life Sciences, United Kingdom), Peter Z. (e184, United Kingdom), Petroula L. (NeuralPulse, United Kingdom), Rajiv M. (Attune Neurosciences, USA), Rishan P. (UCL, United Kingdom), Robert H. (PXN Group, United Kingdom), Robert V. (Asothia, United Kingdom), Roberto P. (Imperial College London, United Kingdom), Romain L. (Nurea, France), Rotem K. (ABILITY Neurotech, Israel), Ruonan D. (Imperial College, United Kingdom), Ryan W. (Outpost VC, USA), Sabine F. (Nurture Capital, Germany), Saira O. (The ONE Campaign, United Kingdom), Sam K. (Myonerv, United Kingdom), Samantha T. (XEIA Venture Partners, USA), Sanem A. (The Sobrato Organization, USA), Sara S. (OneMind, USA), Sepideh N. (Vivamed Inc., USA), Shirine M. (Imperial College London, United Kingdom), Sneh S. (Ceribell, USA), Sophie L. (ETFPartners, United Kingdom), Steve B. (Team Consulting, United Kingdom), Steven C. (UCSF, USA), Suraj M. (Action Potential Venture Capital, USA), Tamar M. (University of Cambridge, United Kingdom), Theresa D. (Foothill Ventures, USA), Toby E. (California Mental Health Services Oversight and Accountabilty Commission, USA), Tracy W. (American Heart Association Venture group, USA), Tyler W. (Madison Scientific, USA), Vasyl M. (the Francis Crick Institute, United Kingdom), Vera D. (Newfund, France), Viggy K. (Sonar Mental Health, USA), Vivien D. (Ryse, United Kingdom), William M. (Nexus Neurotech, USA), Yan L. (Kinteract, United Kingdom), Yige H. (L.E.K. Consulting, USA).
Our raison d’être
In 2013, the European Union launched the Humain Brain Project, and the United States launched the BRAIN Initiative. These efforts were followed by Japan's MINDS program in 2014, and similar initiatives in South Korea, China, and Australia in 2016.
As the scientific advancements from these projects continue to disseminate, we must ensure they translate into real-world innovations that benefit society.We need broad adoption by patients, seamless integration into healthcare systems, and a virtuous cycle where economic gains are reinvested into new discoveries to drive sustained progress.
In 2025, we launched the Brain Tech Alliance to accelerate the translation of science into impact. Our mission is to create a thriving ecosystem that bridges the gap between academia and industry. We support researchers in moving their discoveries from universities to startups, assist startups in securing funding, provide entrepreneurs with opportunities pilot their innovation, and foster collaboration among scientist, investors, and stakeholders. Additionally, we work to raise awareness about the importance of brain health and the urgent need for innovation in this space.
Achieving these goals requires greater investment, stronger commitments, and increased visibility for brain technology. We need more funding, more dedicated champions, and a united effort to drive transformative progress for the betterment of humanity.
The BrainTech Alliance is an initiative led by
.png)
Join the BrainTech Revolution
Be part of the future of brain health. Apply here to join the Alliance.